Cancer is a dynamic and often aggressive disease, making the timely availability of data critical. Interim data can help researchers and clinicians make informed decisions about continuing, modifying, or halting a trial. For instance, if a new drug shows promising results early on, it may be fast-tracked for regulatory approval or expanded access. Conversely, if significant adverse effects are observed, the trial can be stopped early to protect patients.
